Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Wien Med Wochenschr ; 163(21-22): 495-8, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24221053

ABSTRACT

BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of human epidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype. PATIENTS AND METHODS: We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary. RESULTS AND CONCLUSION: Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/pathology , Cell Transformation, Neoplastic/drug effects , Cell Transformation, Neoplastic/genetics , Melanoma/chemically induced , Melanoma/pathology , Molecular Targeted Therapy/adverse effects , Molecular Targeted Therapy/methods , Neoplasms, Multiple Primary/drug therapy , Neoplasms, Multiple Primary/genetics , Neoplasms, Multiple Primary/pathology , Neoplasms, Unknown Primary/chemically induced , Neoplasms, Unknown Primary/pathology , Spinal Cord Neoplasms/chemically induced , Spinal Cord Neoplasms/pathology , Triple Negative Breast Neoplasms/drug therapy , Triple Negative Breast Neoplasms/genetics , Adult , Cell Transformation, Neoplastic/pathology , Combined Modality Therapy , Cyclooxygenase 2/genetics , Disease Progression , ErbB Receptors/genetics , Fatal Outcome , Female , Humans , Ki-67 Antigen/genetics , Melanoma/genetics , Melanoma/secondary , Neoplasm Staging , Neoplasms, Unknown Primary/genetics , Receptor, ErbB-2/genetics , Spinal Cord Neoplasms/genetics , Spinal Cord Neoplasms/secondary , Vascular Endothelial Growth Factor A/genetics
2.
Curr Allergy Asthma Rep ; 12(2): 85-98, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22359067

ABSTRACT

The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti-interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.


Subject(s)
Hypereosinophilic Syndrome/classification , Hypereosinophilic Syndrome/diagnosis , Skin Diseases/diagnosis , Diagnosis, Differential , Humans , Hypereosinophilic Syndrome/genetics , Hypereosinophilic Syndrome/therapy , Skin Diseases/pathology , Skin Diseases/therapy
3.
Arch Dermatol ; 147(8): 963-6, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21482864

ABSTRACT

BACKGROUND: Octopus vulgaris is a common marine animal that can be found in nearly all tropical and semitropical waters around the world. It is a peaceful sea dweller with a parrotlike beak, and its primary defense is to hide through camouflaging adjustments. Bites from animals of the class Cephalopoda are very rare. We describe a boy who was bitten on his forearm by an Octopus vulgaris. OBSERVATION: A 9 -year-old boy was bitten by an Octopus vulgaris while snorkeling. There was no strong bleeding or systemic symptoms; however, 2 days later, a cherry-sized, black, ulcerous lesion developed, surrounded by a red circle that did not heal over months and therefore had to be excised. Histologic examination showed ulceration with extensive necrosis of the dermis and the epidermis. A microbial smear revealed Pseudomonas (formerly known as Flavimonas) oryzihabitans. After excision, the wound healed within 2 weeks, without any complications or signs of infection. CONCLUSIONS: To the best of our knowledge, this case represents the first report of an Octopus vulgaris bite resulting in an ulcerative lesion with slow wound healing owing to P oryzihabitans infection. We recommend greater vigilance regarding bacterial contamination when treating skin lesions caused by marine animals.


Subject(s)
Bites and Stings/complications , Bites and Stings/microbiology , Octopodiformes , Pseudomonas Infections/etiology , Skin Ulcer/etiology , Skin Ulcer/microbiology , Animals , Child , Humans , Male
4.
Expert Opin Emerg Drugs ; 15(2): 249-67, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20433363

ABSTRACT

IMPORTANCE OF THE FIELD: Atopic eczema (AE) is a chronic relapsing inflammatory skin condition and one of the most common, potentially debilitating diseases with increasing incidence. AREAS COVERED IN THIS REVIEW: The complex etiology of AE with multiple systemic and local immunologic and inflammatory responses and interactions between susceptibility genes and environmental factors leading to defects in skin barrier function and eczematous skin lesions is presented. Knowledge of pathogenesis is important for understanding the more innovative treatment approaches discussed. WHAT THE READER WILL GAIN: Basic therapy consists of hydrating topical treatment and avoidance of specific and unspecific provocation factors. For acute eczematous skin lesions, anti-inflammatory treatment consists mainly of topical glucocorticoids and topical calcineurin inhibitors (tacrolimus and pimecrolimus). Microbial colonization and superinfection may induce skin exacerbation, which can be treated by either topical or systemic antimicrobial treatment. Systemic anti-inflammatory therapy is limited to severe cases and consists of systemic steroids, cyclosporine A or mycophenolate mofetil. Novel anti-inflammatory concepts that go beyond corticosteroids are in the early phases of development. There are targeted therapeutic approaches, such as cytokine and chemokine modulators and it remains to be investigated how effective they will be and what side effects they may carry. TAKE HOME MESSAGE: Existing treatment modalities such as barrier repair therapy, topical immunosuppressive agents, antiseptic treatment as well as systemic treatment options are discussed. The review aims to summarize the most recent findings of more innovative treatment approaches such as modulation of cytokines or chemokines, modulation of T-cell responses or anti-IgE therapy.


Subject(s)
Dermatitis, Atopic/drug therapy , Dermatologic Agents/therapeutic use , Drugs, Investigational/therapeutic use , Administration, Cutaneous , Animals , Anti-Infective Agents, Local/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Biological Products/therapeutic use , Dermatitis, Atopic/genetics , Dermatitis, Atopic/immunology , Dermatologic Agents/administration & dosage , Drugs, Investigational/administration & dosage , Humans , Immunosuppressive Agents/therapeutic use , Immunotherapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...